pharmaceutical sales representatives |
|||||
|
pharmaceutical sales representatives News for 24-May-25 Source: MedicineNet Kids Health General Source: MedicineNet Kids Health General Source: MedicineNet Kids Health General Source: MedicineNet Kids Health General Source: MedicineNet Kids Health General Source: MedicineNet Kids Health General Source: MedicineNet Kids Health General Source: MedicineNet Kids Health General Source: MedicineNet Kids Health General Source: MedicineNet Kids Health General
|
The Best pharmaceutical sales representatives websiteAll the pharmaceutical sales representatives information you need to know about is right
here. Presented and researched by http://www.takeyourmeds.info. We've searched
the information super highway far and wide to provide you with the
best pharmaceutical sales representatives site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
pharmaceutical sales representatives
pharmaceutical sales representatives
Internet Shopping for pharmaceutical sales representativesInternet shopping enables us to access many pharmaceutical sales representatives stores and view their offerings from the comfort of our own home. One of the biggest misconceptions about shopping on the Internet for pharmaceutical sales representatives is that it is unsafe and insecure, this is far from the truth. Even if your credit card number is stolen and used to make unauthorized purchases you are not responsible and most credit card companies insure pharmaceutical sales representatives purchases with fraud protection insurance, at no additional cost to you. It is a hassle if your card number is ever stolen but in all actuality you have more of a chance having your card number stolen at a real pharmaceutical sales representatives store than on the Internet. Below are several steps you can take to help ensure safe and secure lg pharmaceutical sales representativesping. It's always good to be familiar with the reputation of any pharmaceutical sales representatives company you're dealing with. To find out more about a company most pharmaceutical sales representatives websites have an ABOUT US section which will tell a little about the organization. Government agencies also monitor the activities of lg pharmaceutical sales representatives to ensure that the goods and services they provide are acceptable to consumers. When you decide to purchase pharmaceutical sales representatives online check out the CONTACT US section of the pharmaceutical sales representatives website to ensure that you can actually contact them by phone, fax or email. Reputable firms will most certainly carry this information. It also pays to check out their returns policy. Many pharmaceutical sales representatives websites offer a no obligation period with a guarantee of full refund of the purchase price if you return the goods in a satisfactory condition. Internet shopping for pharmaceutical sales representatives is rapidly growing and this means high competition between sites selling and marketing pharmaceutical sales representatives goods or services. This competition is good for you because it means everyone selling pharmaceutical sales representatives has to operate their business to high ethical and professional standards. Drug Offers Hope to Cancer Patients by: ARA Content
(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community. Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer. In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow. In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs. Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer. Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy. Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce. Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.
|
||||
|
http://www.medmeet.com/ |
|||||
| Take It Right Internet Meetings Meetings On The Net |